Dr. Reddy’s Laboratories (NYSE:RDY) Releases Earnings Results, Beats Expectations By $0.02 EPS

Posted by Wayne Rhoads on May 11th, 2025

Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) posted its quarterly earnings data on Friday. The company reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.02, Zacks reports. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. The company had revenue of $996.17 million during the quarter, compared to analysts’ expectations of $83.70 billion.

Dr. Reddy’s Laboratories Trading Up 1.8 %

Dr. Reddy’s Laboratories stock opened at $13.42 on Friday. The firm has a 50-day moving average of $13.29 and a 200-day moving average of $14.07. Dr. Reddy’s Laboratories has a one year low of $12.26 and a one year high of $16.89. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. The company has a market cap of $11.20 billion, a price-to-earnings ratio of 21.37 and a beta of 0.33.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Dr. Reddy’s Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday.

Get Our Latest Stock Analysis on Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Company Profile

(Get Free Report)

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.